Arcera Life Sciences and Fosun Pharma Strengthen Global Biotech Innovation with Strategic Collaboration
Partnership Announcement
Abu Dhabi, United Arab Emirates and Shanghai, China – Arcera Life Sciences, a prominent global life sciences company based in Abu Dhabi, has entered into a Memorandum of Understanding (MoU) with Shanghai Fosun Pharmaceutical Group Co., Ltd., a leading innovation-driven global pharmaceutical and healthcare group. This strategic collaboration aims to enhance licensing, technology development, and neuroscience innovation within the global life sciences sector.
The agreement was formalized by Sunil Bhilotra, Chief Investment Officer of Arcera, and Xingli Wang, Co-President of Fosun Pharma and CEO of its Innovative Medicines Division. The signing ceremony was attended by notable figures including Qunbin Wang, Co-Chairman of Fosun International; Yuqing Chen, Chairman of Fosun Pharma; Isabel Afonso, CEO of Arcera; and Rafael Ferrer, Senior Vice President of Corporate Development at Arcera.
Strategic Alignment with Bilateral Goals
This MoU aligns with the Comprehensive Strategic Partnership between the People’s Republic of China and the UAE, as well as Abu Dhabi’s Healthcare Life Sciences Vision 2030. The collaboration aims to create pathways for innovation and market access in both nations. By merging Fosun Pharma’s advanced R&D and manufacturing capabilities with Arcera’s international market access and commercial infrastructure, the partnership positions Abu Dhabi as a vital link between Chinese biotech innovation and global markets. This initiative is expected to accelerate patient access to groundbreaking therapies throughout the Middle East and beyond.
Key Areas of Collaboration
The partnership will focus on three primary areas:
Regional and Global Licensing of Assets: The collaboration will initially identify potential licensing opportunities for Fosun Pharma’s assets in oncology, neuroscience, rare diseases, and cardiometabolic diseases. This includes compounds that are currently in advanced clinical development or commercial stages in China.
Frontier Technology Incubation: The agreement will explore joint ventures or new entities aimed at localizing cutting-edge biotechnology and enhancing sovereign R&D capabilities in the UAE. This will encompass small molecules, biologics, radiopharmaceuticals, small interfering RNA therapies, and cell and gene therapies.
Strategic Collaboration in Neuroscience: The neuroscience initiative will specifically target neurodegenerative diseases, including Alzheimer’s disease programs. This focus addresses a critical global health challenge where both innovative therapeutics and regional access remain significant unmet needs.
Leadership Insights
Isabel Afonso, CEO of Arcera, emphasized the importance of this partnership, stating that it represents a significant step in building a global life sciences ecosystem anchored in the UAE. She noted that combining Fosun Pharma’s drug development capabilities with Arcera’s international commercial and manufacturing strengths will serve as a model for how China-UAE collaboration can enhance biotechnology innovation and patient access to advanced therapies.
Xingli Wang, Co-President of Fosun Pharma, expressed enthusiasm about the strategic partnership, describing it as a pivotal milestone for Fosun Pharma in deepening international collaboration and expanding into global markets. He highlighted Arcera as a formidable industry player and expressed confidence that their combined capabilities would enhance the delivery of innovative therapies in the Middle East and worldwide.
About Arcera Life Sciences
Arcera Life Sciences is a global life sciences company headquartered in Abu Dhabi, United Arab Emirates. The organization aims to enable longer and healthier lives while fostering sustainable growth. Arcera develops, manufactures, and commercializes a wide range of innovative medicines across key international markets. With a presence in over 90 markets and manufacturing facilities in eight countries, the company offers more than 2,000 medicines across various therapeutic areas. Established by ADQ, a sovereign investor focused on critical infrastructure and global supply chains, Arcera aims to position Abu Dhabi as a leader in innovative and sustainable healthcare.
For more information about Arcera, visit www.arceralifesciences.com.
About Fosun Pharma
Founded in 1994, Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group. The company’s mission is to provide better health for families worldwide by developing innovative medicines, medical technologies, and diagnostics, as well as delivering healthcare services. Through its partnership with Sinopharm Group, Fosun Pharma has established a comprehensive pharmaceutical distribution network.
Fosun Pharma is committed to innovation and globalization, with a global R&D innovation system targeting unmet medical needs. The company’s strategic focus includes key therapeutic areas such as oncology, immunology, inflammation, neurodegenerative diseases, and selected cardiometabolic and rare diseases. This approach facilitates the development of competitive pipelines and comprehensive healthcare solutions. Fosun Pharma’s innovative products are now available in over 90 countries and regions worldwide.
For more information about Fosun Pharma, visit Fosun Pharma.
For media inquiries, please contact:
Arcera Life Sciences
Patrick Kerr, VP Corporate Communications: patrick.kerr@arceralifesciences.com or media@arceralifesciences.com
Fosun Pharma
Angel Yi, General Manager of Branding and PR department: pr@fosunpharma.com
Source: www.zawya.com
Read all the latest developments and breaking updates in the Latest News section.
Published on 2026-04-28 18:06:00 • By the Editorial Desk
